Autologous stem cell transplant for high-risk neuroblastoma: Achieving cure with low-cost adaptations.
autologous stem cell transplant
cryopreservation
neuroblastoma
plerixafor
survival
treatment
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
06
01
2020
revised:
16
02
2020
accepted:
02
03
2020
pubmed:
21
3
2020
medline:
18
8
2020
entrez:
21
3
2020
Statut:
ppublish
Résumé
The majority of patients in low- and middle-income countries (LMIC) are unable to receive optimal therapy, including autologous stem cell transplant (ASCT) for high-risk neuroblastoma. Management is intensive and multidisciplinary; survival is often poor. We report a single-center outcome of high-risk neuroblastoma, with adaptations optimized for LMIC. The study was retrospective. Patients were treated on the backbone of the high-risk neuroblastoma study-1 of SIOP-Europe (HR-NBL1/SIOPEN) protocol with ASCT. Adaptations incorporated to decrease cost, requirement for inpatient admission, infections, and faster engraftment included (a) optional outpatient administration for rapid-COJEC, (b) two sessions of stem-cell apheresis, (c) storing stem cells at 2-6°C without cryopreservation for up to 7 days, (d) no central lines, (e) no antibacterial/antifungal/antiviral prophylaxis, (f) omitting formal assessment of cardiac/renal/pulmonary functions before ASCT, and (g) administration of pegylated granulocyte colony-stimulating factor on Day +4. Over 5 years 9 months, 35 patients with high-risk neuroblastoma were treated. Rapid-COJEC was administered over a median duration of 80 days (interquartile range: 77, 83). Conditioning regimen included melphalan (n = 7), oral busulfan-melphalan (Bu/Mel; n = 6), or intravenous Bu/Mel (n = 22). The median viability of stem cells stored for 6 days (n = 28) was 93% (range: 88-99). Two (5.7%) patients had ASCT-related mortality. The 3-year overall and event-free survival was 41% and 39%, respectively. A relapse occurred in 20 (57%) patients. Treatment abandonment was observed in one (3%) patient. Administration of therapy in a disciplined time frame along with low-cost adaptations enables to manage high-risk neuroblastoma with low abandonment and an encouraging survival in LMIC. Stem cells can be stored safely without cryopreservation for up to 7 days.
Sections du résumé
BACKGROUND
The majority of patients in low- and middle-income countries (LMIC) are unable to receive optimal therapy, including autologous stem cell transplant (ASCT) for high-risk neuroblastoma. Management is intensive and multidisciplinary; survival is often poor. We report a single-center outcome of high-risk neuroblastoma, with adaptations optimized for LMIC.
PROCEDURE
The study was retrospective. Patients were treated on the backbone of the high-risk neuroblastoma study-1 of SIOP-Europe (HR-NBL1/SIOPEN) protocol with ASCT. Adaptations incorporated to decrease cost, requirement for inpatient admission, infections, and faster engraftment included (a) optional outpatient administration for rapid-COJEC, (b) two sessions of stem-cell apheresis, (c) storing stem cells at 2-6°C without cryopreservation for up to 7 days, (d) no central lines, (e) no antibacterial/antifungal/antiviral prophylaxis, (f) omitting formal assessment of cardiac/renal/pulmonary functions before ASCT, and (g) administration of pegylated granulocyte colony-stimulating factor on Day +4.
RESULTS
Over 5 years 9 months, 35 patients with high-risk neuroblastoma were treated. Rapid-COJEC was administered over a median duration of 80 days (interquartile range: 77, 83). Conditioning regimen included melphalan (n = 7), oral busulfan-melphalan (Bu/Mel; n = 6), or intravenous Bu/Mel (n = 22). The median viability of stem cells stored for 6 days (n = 28) was 93% (range: 88-99). Two (5.7%) patients had ASCT-related mortality. The 3-year overall and event-free survival was 41% and 39%, respectively. A relapse occurred in 20 (57%) patients. Treatment abandonment was observed in one (3%) patient.
CONCLUSIONS
Administration of therapy in a disciplined time frame along with low-cost adaptations enables to manage high-risk neuroblastoma with low abandonment and an encouraging survival in LMIC. Stem cells can be stored safely without cryopreservation for up to 7 days.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28273Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Ladenstein R, Pötschger U, Pearson ADJ, et al., Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol. 2017;18:500-514.
Kreissman SG, Villablanca JG, Seeger RC, et al. A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: a Children's Oncology Group study. J Clin Oncol. 2008;26(suppl):10011.
Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group study. J Clin Oncol. 2009;27:1007-1013.
Kushner BH, Ostrovnaya I, Cheung IY, et al. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. Oncotarget. 2016;7:4155-4166.
Philip T, Ladenstein R, Lasset C, et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. Eur J Cancer. 1997;33:2130-2135.
Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am. 2010;24:65-86.
Desai AV, Heneghan MB, Li Y, et al. Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma. Bone Marrow Transplant. 2016;51:1204-1210.
Agarwala S, Mandelia A, Bakhshi S, et al. Neuroblastoma: outcome over a 14 year period from a tertiary care referral center in India. J Pediatr Surg. 2014;49:1280-1285.
Bansal D, Marwaha RK, Trehan A, Rao KL, Gupta V. Profile and outcome of neuroblastoma with conventional chemotherapy in children older than one year: a 15 year experience. Indian Pediatr. 2008;45:135-139.
Cai J, Pan C, Tang Y, et al. Multivariate analysis of risk factors for patients with stage 4 neuroblastoma who were older than 18 months at diagnosis: a report from a single institute in Shanghai, China. J Cancer Res Clin Oncol. 2017;143:1327-1335.
Al-Tonbary Y, Badr M, Mansour A, et al. Clinico-epidemiology of neuroblastoma in north east Egypt: a 5-year multicenter study. Oncol Lett. 2015;10:1054-1062.
Aksoylar S, Varan A, Vergin C, et al. Treatment of high-risk neuroblastoma: national protocol results of the Turkish Pediatric Oncology Group. J Cancer Res Ther. 2017;13:284-290.
Kusumakumari P, Ajithkumar TV, Hariharan S, et al. Intensive chemotherapy in children with stage IV neuroblastoma. Indian J Pediatr. 1999;66:867-872.
Radhakrishnan V, Raja A, Dhanushkodi M, et al. Real World Experience of Treating Neuroblastoma: experience from a Tertiary Cancer Center in India. Indian J Pediatr. 2019;86:417-426.
Parikh NS, Howard SC, Chantada G, et al. International Society of Pediatric Oncology. SIOP-PODC adapted risk stratification and treatment guidelines: recommendations for neuroblastoma in low- and middle-income settings. Pediatr Blood Cancer. 2015;62:1305-1316.
Bansal D, Totadri S, Chinnaswamy G, et al. Management of neuroblastoma: iCMR consensus document. Indian J Pediatr. 2017;84:446-455.
Bhargav A, Singh U, Trehan A, Zadeng Z, Bansal D. Female sex, bilateral disease, age below 3 years, and apprehension for enucleation contribute to treatment abandonment in retinoblastoma. J Pediatr Hematol Oncol. 2017;39:e249-e253.
Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466-1477.
Koshy A, Jain R, Srinivasan R, et al. Cytopathological spectrum of peripheral neuroblastic tumours in fine needle aspiration cytology and categorisation as per international neuroblastoma pathology classification. Cytopathology. 2019;30:634-643.
WHO. WHO Anthro (version 3.2.2) and macros. Geneva: WHO; 2011. http://www.who.int/childgrowth/software/. Accessed September 17, 2019.
WHO. WHO AnthroPlus for personal computers: software for assessing growth of the world ’s children and adolescents. Geneva: WHO; 2009. http://www.who.int/growthref/tools/en/
WHO. WHO global database on child growth and malnutrition. Geneva: WHO; 2016. http://www.who.int/nutgrowthdb/about/introduction/en/
NIH. High-risk neuroblastoma study 1.8 of SIOP-Europe (SIOPEN)/UK version/ August 2002/amended July 2007.
National Cancer Institute, National Institute of Health. Common terminology criteria for adverse events. 2010. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
Howard SC, Davidson A, Luna-Fineman S, et al. A framework to develop adapted treatment regimens to manage pediatric cancer in low- and middle-income countries: the Pediatric Oncology in Developing Countries (PODC) Committee of the International Pediatric Oncology Society (SIOP). Pediatr Blood Cancer. 2017;64:e26879.
Vaishnavi K, Bansal D, Trehan A, et al. Improving the safety of high-dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin. Pediatr Blood Cancer. 2018;65:e27241.
Bansal D, Davidson A, Supriyadi E, et al. SIOP PODC adapted risk stratification and treatment guidelines: recommendations for acute myeloid leukemia in resource-limited settings. Pediatr Blood Cancer. 2019:e28087.
Kreissman SG, Seeger RC, Matthay KK, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A 3973): a randomised phase 3 trial. Lancet Oncol. 2013;14:999-1008.
Sutaryo S, Kristian S. A five-year review of children with neuroblastoma at Dr. Sardjito General Hospital, Yogyakarta, Indonesia. 2019;59(3):157-163. https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/2145.
Mehdiabadi GB, Arab E, Rafsanjani KA, Ansari S, Moinzadeh AM. Neuroblastoma in Iran: an experience of 32 years at a referral childrens hospital. Asian Pac J Cancer Prev. 2013;14(5):2739-2742.
Van Heerden J, Hendricks M, Geel J, et al. Overall survival for neuroblastoma in South Africa between 2000 and 2014. Pediatr Blood Cancer. 2019;66:e27944.
National Family Health Survey. Key findings from NFHS-4. http://rchiips.org/nfhs/pdf/NFHS4/India.pdf. Accessed September 19, 2019.
Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341:1165-1173.
Naithani R, Sachdeva M, Rai R, Dayal N. Plerixafor for hematopoietic stem cell mobilization in children with neuroblastoma. Exp Clin Transplant. 2016;14:358-359.
Maschan AA, Balashov DN, Kurnikova EE, et al. Efficacy of plerixafor in children with malignant tumors failing to mobilize a sufficient number of hematopoietic progenitors with G-CSF. Bone Marrow Transplant. 2015;50:1089-1091.
Douglas KW, Gilleece M, Hayden P, et al. UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy. J Clin Apher. 2018;33:46-59.
Kardduss-Urueta A, Gale RP, Gutierrez-Aguirre CH, et al. Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas. Bone Marrow Transplant. 2018;53:457-460.
Sarmiento M, Ramírez P, Parody R, et al. Advantages of non-cryopreserved autologous hematopoietic stem cell transplantation against a cryopreserved strategy. Bone Marrow Transplant. 2018;53:960-966.
Cuellar-Ambrosi F, Karduss UA, Gomez WR, et al. Hematologic reconstitution following high-dose and supralethal chemoradiotherapy using stored, noncryopreserved autologous hematopoietic stem cells. Transplant Proc. 2004;36:1704-1705.
Ramzi M, Mohamadian M, Vojdani R, et al. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol. Exp Clin Transplant. 2012;10:163-167.
London WB, Bagatell R, Weigel BJ, et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. Cancer. 2017;123:4914-4923.
Al-Faraj E, Millar BA, Irwin MS, Gupta A. Isolated late CNS relapse in a young adult 10 years after initial treatment for neuroblastoma. J Pediatr Hematol Oncol. 2015;37:75-77.